| [1] |
WANG Zhiqing, LIU Xiyu, FAN Lei.
Advances and controversies in the adjuvant treatment of early breast cancer
[J]. China Oncology, 2025, 35(3): 255-262.
|
| [2] |
ZHAO Kaile, WANG Lei, GENG Jianxiong, CUI Chengwei, YU Yan.
Research status and prospects of treatment for malignant pleural mesothelioma
[J]. China Oncology, 2025, 35(3): 326-332.
|
| [3] |
AN Tianqi, TIAN Jianhui, ZHOU Yiyang, LUO Bin, QUE Zujun, LIU Yao, YU Pan, ZHAO Ruihua, YANG Yun.
Research progress on treatment of pleural effusion related to immune checkpoint inhibitors
[J]. China Oncology, 2025, 35(3): 333-338.
|
| [4] |
LAN Yu, WANG Fenghua.
Comparison and review of updated guidelines for advanced gastric cancer diagnosis and treatment in 2024: CSCO, NCCN and ESMO
[J]. China Oncology, 2025, 35(2): 219-227.
|
| [5] |
CAI Shuyue, XIE Quan, ZHOU Yuxuan, LIU Qingzhu, QIU Ling, LIN Jianguo.
Latest progress and prospect of NRP-1 targeted molecular probes for breast cancer diagnosis
[J]. China Oncology, 2025, 35(2): 249-254.
|
| [6] |
ZHAO Yihan, LI Ruochen, LIN Yansong.
Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer
[J]. China Oncology, 2025, 35(1): 12-20.
|
| [7] |
WANG Renfei, LU Gaixia.
The unique value and controversy of nuclear medicine molecular imaging in the evaluation of radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 49-57.
|
| [8] |
Society of Neuroendocrine Neoplasm of China Anti-Cancer Association.
China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition)
[J]. China Oncology, 2025, 35(1): 85-142.
|
| [9] |
Cancer Assessment Society of China Anti-Cancer Association, Cancer Pain Society of Fujian Anti-Cancer Association.
Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition)
[J]. China Oncology, 2024, 34(8): 785-805.
|
| [10] |
LIU Shuai, ZHANG Kai, ZHANG Xiaoqing, LUAN Wei.
An exploratory study on the perioperative treatment of locally advanced gastric cancer with combination of penpulimab, anlotinib and chemotherapy
[J]. China Oncology, 2024, 34(7): 659-668.
|
| [11] |
CHEN Hong, CAO Zhiyun.
Recent progress in the construction and application of patient-derived pancreatic cancer organoid models
[J]. China Oncology, 2024, 34(6): 590-597.
|
| [12] |
Urologic Chinese Oncology Group.
Expert consensus on early diagnosis and treatment of bladder cancer (2024 edition)
[J]. China Oncology, 2024, 34(6): 607-618.
|
| [13] |
Professional Committee on Gastric Cancer of Shanghai Anticancer Association , Professional Committee on Gastrointestinal Cancer of China Association for Promotion of Health Science and Technology .
Chinese expert consensus on clinical practice of locally advanced gastric cancer invading adjacent organs (2024 edition)
[J]. China Oncology, 2024, 34(5): 517-526.
|
| [14] |
FENG Zheng, GUO Qinhao, ZHU Jun, WU Xiaohua, WEN Hao.
Progress in treatment of gynecological cancer in 2023
[J]. China Oncology, 2024, 34(4): 340-360.
|
| [15] |
MA Fenghua, JIANG Anqi, CHEN Yiqing, XU Congjian, KANG Yu.
Magnetic resonance imaging for distinguishing gastric-type endocervical adenocarcinoma from lobular endocervical glandular hyperplasia
[J]. China Oncology, 2024, 34(4): 380-388.
|
